# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst Colin Bristow maintains Immunovant (NASDAQ:IMVT) with a Buy and lowers the price target from $42 to $41.
JP Morgan analyst Brian Cheng maintains Immunovant (NASDAQ:IMVT) with a Overweight and lowers the price target from $51 to $46.
Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.
Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.53) ...
Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.
Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.
Oppenheimer analyst Leland Gershell maintains Immunovant (NASDAQ:IMVT) with a Outperform and lowers the price target from $5...
Cantor Fitzgerald analyst Louise Chen reiterates Immunovant (NASDAQ:IMVT) with a Overweight.
HC Wainwright & Co. analyst Douglas Tsao reiterates Immunovant (NASDAQ:IMVT) with a Buy and maintains $51 price target.